Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nova Mentis Life Science Corp. C.LIB

Healthcare Drug Manufacturers - Major Cannabis
Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the cultivation of AAAA premium, small batch, terpene rich dominant cultivars cured to perfection.


CSE:LIB - Post by User

Nova Mentis Life Science Corp. > Private Placement
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
Comment by Islandcron Jan 21, 2018 7:51pm
185 Views
Post# 27405180

RE:Private Placement

RE:Private PlacementThis really shouldn't be allowed, at the very least they should have to amend the filing as the price has been well above that .40 (more than double) for weeks. I could see if it was tied to a transaction / acquisition of something but it's clearly not according to the filing.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities